Co-led by Professor Jamie Rossjohn of Monash University and Associate Professor Andrew Brooks from University of Melbourne, an international team of scientists have discovered more about the critical role Natural Killer cells play in the body's innate immune response.
The findings were published today in Nature.
Natural Killer cells are a unique type of white blood cell important in early immune responses to tumours and viruses. Unlike most cells of the immune system that are activated by molecules found on the pathogen or tumour, Natural Killer cells are shut down by a group of proteins found on healthy cells.
These de-activating proteins, known as Human Leukocyte Antigens or HLA molecules are absent in many tumours and cells infected with viruses, leaving them open to attack by the Natural Killer cells.
Natural Killer cells recognise the HLA molecules using an inbuilt surveillance system called "Killer cell immunoglobulin-like receptors" (KIR).
Using the Australian Synchrotron, the team determined the three dimensional shape of one of these key KIR proteins, termed KIR3DL1, which binds to a particular HLA molecule.
This pairing is known to play a role in limiting viral replication in people with HIV, slowing the progression of the disease to AIDS.
Professor Rossjohn said that better understanding the structure of KIR proteins may help to develop approaches to better utilise Natural Killer cells to combat viral infection.
"It is only possible to detect proteins, such as KIRs, using extremely high-end equipment. The use of the platform technologies at Monash and the Australian Synchrotron was absolutely essential to this project’s success," Professor Rossjohn said.
Professor Brooks said the researchers would use these findings to investigate other KIR molecules.
"Since KIR3DL1 is only a single member of a much larger family of receptors, the study provides key insight into how Natural Killer cells utilise other members of this important family of receptors to recognise virus-infected cells and tumours," Professor Brooks said.
The five-year project involved international collaborations with researchers from the National Cancer Institute-Frederick, National Institute of Allergy and Infectious Diseases, National Institutes of Health and Cardiff University School of Medicine.
The research was funded by the National Health and Medical Research Council, the Australian Research Council, the Intramural Research Programs of the National Cancer Institute, the National Cancer Institute of Allergy and Infectious Diseases, Medical Research Council (UK) and National Institutes of Health.
